» Articles » PMID: 23361117

Portal Vein Embolization Before Right Hepatectomy: Improved Results Using N-butyl-cyanoacrylate Compared to Microparticles Plus Coils

Overview
Date 2013 Jan 31
PMID 23361117
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There is currently no consensus in the literature on which embolic agent induces the greatest degree of liver hypertrophy after portal vein embolization (PVE). Only experimental results in a pig model have demonstrated an advantage of n-butyl-cyanoacrylate (NBCA) over 3 other embolic materials (hydrophilic gel, small and large polyvinyl alcohol particles) for PVE. Therefore, the aim of this human study was to retrospectively compare the results of PVE using NBCA with those using spherical microparticles plus coils.

Methods: A total of 34 patients underwent PVE using either NBCA (n = 20), or spherical microparticles plus coils (n = 14). PVE was decided according to preoperative volumetry on the basis of contrast-enhanced CT. Groups were compared for age, sex, volume of the left lobe before PVE and future remnant liver ratio (FRL) (volume of the left lobe/total liver volume - tumor volume). The primary end point was the increase in left lobe volume 1 month after PVE. Secondary end points were procedure complications and biological tolerance.

Results: Both groups were similar in terms of age, sex ratio, left lobe volume, and FRL before PVE. NBCA induced a greater increase in volume after PVE than did microparticles plus coils (respectively, +74 ± 69 % and +23 ± 14 %, p < 0.05). The amount of contrast medium used for the procedure was significantly larger when microparticles and coils rather than NBCA were used (respectively, 264 ± 43 ml and 162 ± 34 ml, p < 0.01). The rate of PVE complications as well as the biological tolerance was similar in both groups.

Conclusion: NBCA seems more effective than spherical microparticles plus coils to induce left-lobe hypertrophy.

Citing Articles

CIRSE Standards of Practice on Portal Vein Embolization and Double Vein Embolization/Liver Venous Deprivation.

Bilhim T, Boning G, Guiu B, Luz J, Denys A Cardiovasc Intervent Radiol. 2024; 47(8):1025-1036.

PMID: 38884781 PMC: 11303578. DOI: 10.1007/s00270-024-03743-8.


Portal vein embolization with N-butyl-cyanoacrylate improves liver hypertrophy compared to microparticles - A Swedish multicenter cohort study.

Bjork D, Delle M, Holmquist F, Hasselgren K, Sandstrom P, Lindell G Heliyon. 2023; 9(11):e21210.

PMID: 37954304 PMC: 10637931. DOI: 10.1016/j.heliyon.2023.e21210.


Imaging-guided interventions modulating portal venous flow: Evidence and controversies.

Cannella R, Tselikas L, Douane F, Cauchy F, Rautou P, Duran R JHEP Rep. 2022; 4(7):100484.

PMID: 35677591 PMC: 9168703. DOI: 10.1016/j.jhepr.2022.100484.


Portal Vein Embolization Using N-Butyl Cyanoacrylate-Glue: What Impact Does a Central Vascular Plug Have?.

Carling U, Rosok B, Berger S, Fretland A, Dorenberg E Cardiovasc Intervent Radiol. 2021; 45(4):450-458.

PMID: 34907454 PMC: 8940786. DOI: 10.1007/s00270-021-03014-w.


Predictive Factors for Hypertrophy of the Future Liver Remnant After Portal Vein Embolization: A Systematic Review.

Soykan E, Aarts B, Lopez-Yurda M, Kuhlmann K, Erdmann J, Kok N Cardiovasc Intervent Radiol. 2021; 44(9):1355-1366.

PMID: 34142192 PMC: 8382618. DOI: 10.1007/s00270-021-02877-3.